 | Up a level |
D'Ambrosio, Lorenzo, Touati, Nathan, Blay, Jean-Yves 
ORCID: 0000-0001-7190-120X, Grignani, Giovanni, Flippot, Ronan, Czarnecka, Anna M., Piperno-Neumann, Sophie, Martin-Broto, Javier ORCID: 0000-0001-7350-6916, Sanfilippo, Roberta, Katz, Daniela, Duffaud, Florence, Vincenzi, Bruno, Stark, Daniel P., Mazzeo, Filomena, Tuchscherer, Armin, Chevreau, Christine, Sherriff, Jenny, Estival, Anna, Litiere, Saskia, Sents, Ward, Ray-Coquard, Isabelle, Tolomeo, Francesco, Le Cesne, Axel, Rutkowski, Piotr, Stacchiotti, Silvia, Kasper, Bernd, Gelderblom, Hans and Gronchi, Alessandro
(2020).
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Cancer, 126 (11).
S. 2637 - 2648.
HOBOKEN:
WILEY.
ISSN 1097-0142